Oklo Inc vs Vaxcyte Inc. Common Stock — how do they compare? Oklo Inc trades at $28.7 (market cap $5.91B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oklo Inc for 33 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| OKLO | PCVX | |
|---|---|---|
Market Cap | $5.91B | $10.51B |
Volume | 8,898,651 | 2,644,694 |
Sector | Utilities | Health |
52-Week High | $171.56 | $73.82 |
52-Week Low | $29.04 | $40.32 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $3.45B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $31.78, down 1.33% on the day, with a bearish technical signal despite oversold RSI readings. The company shows no revenue in 2025 and a net loss of $105.66 million, with negative profit margins and ROE. Recent news highlights competition in the nuclear sector and OKLO's $1 billion stock sale, while analyst consensus remains strongly bullish with a $78.63 price target.
OKLO presents high-risk, high-reward potential as an early-stage nuclear company. The bullish analyst outlook and strategic project pipeline offer upside, but significant execution risks, cash burn, and competitive pressures require careful consideration. Investor sentiment is mixed amid operational challenges and dilution concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →